Combination of Huperzine and Nicotinic Compounds as a Neuroprotective Agent
Categories: “Neurological Disorders“
Reference #: 2000-038
OTC Contact: Tracy Bruehs, M.S., J.D. (Directory Information | Send a Message)
Georgetown University is seeking a partner in the development and commercialization of the combination of huperzine and nicotine to ameliorate memory loss.
This technology encompasses compositions and methods for treating and alleviating or reversing memory disorders including those associated with neurodegenerative diseases including among others Alzheimer’s disease. This invention can also be used to slow the progression of these diseases, using huperzine A in combination with a nicotinic compound. It is believed that this combination protects brain and spinal cord neurons in culture against death due to several known damaging agents, including -amyloid (which is believed to be critical to the pathology of Alzheimer’s disease), glutamate (which is thought to be a critical agent in killing neurons during and after stroke, as well as other insults), and hypoxia/hypoglycemia.
- New composition may be taken at earliest signs of mild cognitive impairment or when asymptomatic to prevent onset of disease;
- Combination may be applied through transdermal patch allowing for multiple day dosing or through other delivery devices;
- Huperzine has been consistently shown to be safe and tolerable; nicotine can be administered at very low doses to achieve desired effect.
Stage of Development
No reduction to practice of combination technology.
No references or resources available.
Issued US Patent 6,369,052, on April 9, 2002. Fully paid-up.